166 related articles for article (PubMed ID: 36201744)
1. Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects.
Patterson MT; Khan SM; Nunes NS; Fletcher RE; Bian J; Hadjis AD; Eckhaus MA; Mendu SK; de Paula Pohl A; Venzon DJ; Choo-Wosoba H; Ishii K; Qin H; Fry TJ; Cam M; Kanakry CG
Blood; 2023 Feb; 141(6):659-672. PubMed ID: 36201744
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
Nunes NS; Kanakry CG
Front Immunol; 2019; 10():2668. PubMed ID: 31849930
[TBL] [Abstract][Full Text] [Related]
3. Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4
Hadjis AD; Nunes NS; Khan SM; Fletcher RE; Pohl AP; Venzon DJ; Eckhaus MA; Kanakry CG
Front Immunol; 2022; 13():796349. PubMed ID: 35242129
[TBL] [Abstract][Full Text] [Related]
4. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.
Wachsmuth LP; Patterson MT; Eckhaus MA; Venzon DJ; Gress RE; Kanakry CG
J Clin Invest; 2019 Mar; 129(6):2357-2373. PubMed ID: 30913039
[TBL] [Abstract][Full Text] [Related]
5. Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation.
Wachsmuth LP; Patterson MT; Eckhaus MA; Venzon DJ; Kanakry CG
Biol Blood Marrow Transplant; 2020 Feb; 26(2):230-241. PubMed ID: 31586477
[TBL] [Abstract][Full Text] [Related]
6. Increased Infections and Delayed CD4
Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
[TBL] [Abstract][Full Text] [Related]
7. Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs.
Fletcher RE; Nunes NS; Patterson MT; Vinod N; Khan SM; Mendu SK; Li X; de Paula Pohl A; Wachsmuth LP; Choo-Wosoba H; Eckhaus MA; Venzon DJ; Kanakry CG
Blood Adv; 2023 Apr; 7(7):1117-1129. PubMed ID: 36595377
[TBL] [Abstract][Full Text] [Related]
8. Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.
Nakamae H
Int J Hematol; 2022 Oct; 116(4):465-481. PubMed ID: 35930118
[TBL] [Abstract][Full Text] [Related]
9. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT).
Ortí G; Gras L; Koster L; Kulagin A; Byrne J; Apperley JF; Halaburda K; Blau IW; Clark A; Kröger N; Griskevicius L; Carlson K; Collin M; Bloor A; Raiola AM; Blaise D; Aljurf M; López-Corral L; Sakellari I; Beguin Y; Wrobel T; de Rosa L; de Lavallade H; Hayden PJ; McLornan D; Chalandon Y; Yakoub-Agha I
Transplant Cell Ther; 2024 Jan; 30(1):93.e1-93.e12. PubMed ID: 37783337
[TBL] [Abstract][Full Text] [Related]
11. Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model.
Makuuchi Y; Nakashima Y; Nishimoto M; Koh H; Hino M; Nakamae H
Exp Hematol; 2023 Jul; 123():56-65. PubMed ID: 37098360
[TBL] [Abstract][Full Text] [Related]
12. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation.
Chhabra S; Jerkins JH; Monahan K; Szabo A; Shah NN; Abedin S; Runaas L; Fenske TS; Pasquini MC; Shaw BE; Drobyski WR; Saber W; D'Souza A; Dhakal B; Mohan M; Longo W; Hamadani M
Bone Marrow Transplant; 2024 Mar; 59(3):373-379. PubMed ID: 38177221
[TBL] [Abstract][Full Text] [Related]
13. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
[TBL] [Abstract][Full Text] [Related]
14. Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?
Mohty R; Al Kadhimi Z; Kharfan-Dabaja M
Hematology; 2024 Dec; 29(1):2326384. PubMed ID: 38597828
[TBL] [Abstract][Full Text] [Related]
15. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
[TBL] [Abstract][Full Text] [Related]
16. Effect of Graft-versus-Host Disease on Post-Transplantation Outcomes following Single Cord Blood Transplantation Compared with Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Adult Acute Myeloid Leukemia.
Konuma T; Matsuda K; Shimomura Y; Tanoue S; Sugita J; Inamoto Y; Hirayama M; Ara T; Nakamae H; Ota S; Maruyama Y; Eto T; Uchida N; Tanaka M; Ishiwata K; Koi S; Takahashi S; Ozawa Y; Onizuka M; Kanda Y; Kimura T; Ichinohe T; Atsuta Y; Kanda J; Yanada M
Transplant Cell Ther; 2023 Jun; 29(6):365.e1-365.e11. PubMed ID: 36889507
[TBL] [Abstract][Full Text] [Related]
17. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
18. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
Ahmed S; Kanakry JA; Ahn KW; Litovich C; Abdel-Azim H; Aljurf M; Bacher VU; Bejanyan N; Cohen JB; Farooq U; Fuchs EJ; Bolaños-Meade J; Ghosh N; Herrera AF; Hossain NM; Inwards D; Kanate AS; Martino R; Munshi PN; Murthy H; Mussetti A; Nieto Y; Perales MA; Romee R; Savani BN; Seo S; Wirk B; Yared JA; Sureda A; Fenske TS; Hamadani M
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1859-1868. PubMed ID: 31132455
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Papanicolaou GA; Chen M; He N; Martens MJ; Kim S; Batista MV; Bhatt NS; Hematti P; Hill JA; Liu H; Nathan S; Seftel MD; Sharma A; Waller EK; Wingard JR; Young JH; Dandoy CE; Perales MA; Chemaly RF; Riches M; Ustun C
Transplant Cell Ther; 2024 Jan; 30(1):114.e1-114.e16. PubMed ID: 37775070
[TBL] [Abstract][Full Text] [Related]
20. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
[Next] [New Search]
